Clinical trials: Metastasis
Melanoma (Skin)
Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma
RATIONALE: Treating lymphocytes in the laboratory may help the lymphocytes kill more tumor cells when they are put back in the body. Aldesleukin may stimulate the lymphocytes to kill tumor cells.
- Trial name
- NCT00863330
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Geographic Atrophy Secondary to Age-related Macular Degeneration
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who…
- Trial name
- GALE (NCT04770545)
- Testing
- PEGCETACOPLAN (APL-2)
- Where
- 175 sites in United States, Argentina and 13 more
- Volunteers
- 792 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Neoplasms, Gastrointestinal Tract
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
This was an international multi-center trial that enrolled patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors had amplification of the ErbB2 (HER2)…
- Trial name
- NCT00680901
- Testing
- Lapatinib, Capecitabine, Oxaliplatin
- Where
- 183 sites in United States, Argentina and 21 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR
- Trial name
- NCT02207530
- Testing
- MEDI4736
- Where
- 108 sites in United States, Belgium and 12 more
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Breast Cancer, Chemotherapeutic Agent Toxicity
L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer
RATIONALE: L-carnitine L-tartrate may prevent peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well L-carnitine L-tartrate works in preventing peripheral neuropathy caused by…
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Neurotoxicity
- Trial name
- NCT00754767
- Testing
- L-carnitine L-tartrate
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- HealthPartners Institute
Non-Small-Cell Lung Cancer
A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer
This study will estimate the response rate in patients with advanced or metastatic non-squamous Non-Small Cell Lung Cancer. Patients who don't progress after 4 to 6 cycles of induction treatment with pemetrexed, cisplatin and…
- Trial name
- NCT00867009
- Testing
- Pemetrexed, Cisplatin, Cetuximab
- Where
- 24 sites in Austria, Germany and 4 more
- Volunteers
- 113 people
- Sponsor
- Eli Lilly and Company
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors.
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- IMAGINE (NCT04637594)
- Testing
- Pembrolizumab, Nivolumab, Atezolizumab
- Where
- 377 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neuroendocrine Tumors, Von Hippel-Lindau Syndrome
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Background: Neuroendocrine tumors (NETs) are rare but have been more common over the past decade. The only treatment for NETs is surgery, but most are found when they are too advanced for surgery.
- Conditions
- Neuroendocrine Tumors, Von Hippel-Lindau Syndrome, Hippel-Lindau Disease
- Trial name
- NCT01967537
- Testing
- 68Gallium DOTATATE, Radio-guided surgery
- Where
- United States
- Volunteers
- 341 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)
This is an open-label, non-randomized, sequentially enrolling single arm phase II trial to evaluate the activity of TAS-102 in previously treated metastatic and locally advanced unresectable pancreatic cancer after progression…
- Trial name
- NCT02921737
- Testing
- TAS-102
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Florida
Migraine, Medication Overuse Headache
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins).
- Trial name
- RESOLUTION (NCT05452239)
- Testing
- Eptinezumab
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 608 people
- Sponsor
- H. Lundbeck A/S
Kidney Cancer
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00459875
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma, Advanced Melanoma
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
CMP-001-011 is a Phase 2/3 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) compared to nivolumab monotherapy administered to participants with unresectable or metastatic melanoma.
- Conditions
- Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
- Trial name
- NCT04695977
- Testing
- CMP-001, Nivolumab
- Where
- 20 sites in United States
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals
Esophageal Neoplasms, Stomach Neoplasms
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
The purpose of this study is to evaluate the progression free survival of capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) in previously untreated metastatic esophagogastric adenocarcinomas.
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis
- Trial name
- XAGastric (NCT00447330)
- Testing
- capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Prostate Cancer
A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
This is a single-arm pharmacodynamic study with mandatory metastatic tumor biopsies in men with castration-resistant prostate cancer.
- Trial name
- NCT02115828
- Testing
- Vismodegib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Castration-Resistant Prostatic Cancer
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
- Trial name
- MAGNITUDE (NCT03748641)
- Testing
- Niraparib, Abiraterone Acetate, Prednisone
- Where
- 318 sites in United States, Argentina and 27 more
- Volunteers
- 765 people
- Sponsor
- Janssen Research & Development, LLC
Lung Cancer
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in…
- Trial name
- NCT03322566
- Testing
- Pembrolizumab, Epacadostat, Platinum-based chemotherapy
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 233 people
- Sponsor
- Incyte Corporation
Melanoma (Skin)
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
RATIONALE: Pegylated arginine deiminase may stop the growth of tumor cells by taking away an amino acid needed for cell growth. PURPOSE: This phase II trial is studying how well pegylated arginine deiminase works in treating…
- Trial name
- NCT00450372
- Testing
- ADI-PEG-20, Pharmacology Studies
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Miami
Head and Neck Cancer
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line…
- Trial name
- NCT03358472
- Testing
- Pembrolizumab, Epacadostat, Cetuximab
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 89 people
- Sponsor
- Incyte Corporation
Melanoma
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
This study will examine the effectiveness and safety of glembatumumab vedotin as monotherapy or in combination with immunotherapies in patients with advanced melanoma.
- Trial name
- NCT02302339
- Testing
- glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
- Where
- 14 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with…
- Trial name
- NCT02340975
- Testing
- MEDI4736 + tremelimumab, MEDI4736, Tremelimumab
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 114 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.